Effect of immunologic intervention on in vivo murine Rous sarcoma virus tumorigenesis
Banks, R.A.; Babcock, G.F.; Whitmore, A.C.; Haughton, G.
Journal of the National Cancer Institute 63(6): 1423-1431
1979
ISSN/ISBN: 0027-8874 PMID: 229292 Document Number: 140414
The effect of immunologic manipulation on the development of primary murine Rous sarcoma was examined after neonatal injection of Rous sarcoma virus-induced chicken tumor material (RCTM) into mice. Heterologous antithymocyte serum (ATS) treatment of mice beginning at 7 and 21 days of age tripled and nearly doubled, respectively, the incidence of primary Rous sarcoma, but treatment at 21 days significantly prolonged the mean latency period of the resultant tumors. Also studied was the effect of an i.p. injection of syngeneic adult mouse lymphoid cells, either normal or sensitized, on primary Rous sarcoma incidence. Lymphoid cells from syngeneic adult mice immunized with allogeneic Rous sarcomas (and resistant to syngeneic tumor challenge) had no effect when the animals received injections at birth (day 1), but immune lymph node cells (LNC) significantly increased tumor incidence when animals were given injections of LNC 1 wk after birth and injections of RCTM on day 1. LNC and spleen cells (SC) from syngeneic adult mice that had been inoculated with RCTM at birth but had not developed tumors by 200 days of age (V+T-) decreased tumor incidence when administered on day 1 but not on day 7. Normal adult SC and LNC had no effect when given on day 1 but significantly increased tumor incidence when given on day 7. The tumor-stimulating activity of normal lymphoid cells administered on day 7 was observed both in the relatively susceptible strain C57BL/10ScSn mice and the resistant H-2 congenic strain B10.D2. Serum from adult immune, V+T- [virus-positive, tumor-negative], and T+ [tumor-positive] mice administered on days 1 and 7 decreased primary tumor incidence, though only the effect of T+ serum was statistically significant. The offspring of immune mothers were less susceptible than those of normal mothers. The offspring of passively immunized mothers given serum from immune females during pregnancy were more susceptible than controls. RCTM-inoculated mice were apparently susceptible only to immunologic manipulations that reduced primary tumor incidence during the first few days of life. After 7 days of age, all treatments had no net effect or increased tumor incidence, though ATS treatment beginning at day 21 significantly lengthened the mean tumor latency period.